Trial involved over 450 women across Europe, Turkey and Canada who were unsuitable for hormone therapy
News
Positive results for Evgen’s rhabdomyosarcoma therapy
Update on radiosensitising impact of SFX-01 when treating common soft tissue sarcoma condition
MinervaX reveals completion of vaccine trial enrolment
The company is seeking to address the worldwide impact of group B streptococcus in older adults
CHMP gives positive opinion recommending authorisation to GSK’s CKD drug
Chronic kidney disease affects roughly 700 million patients worldwide
AstraZeneca’s Soliris given EU CHMP recommendation for marketing authorisation
The authorisation would include certain patients with refractory generalised myasthenia gravis
Blood Cancer UK extends collaboration with RareCan
The organisations will focus on the delivery of clinical trials which concentrate on rare cancers
Nanopharmaceutics and PrecisionLife in research collaboration
Companies’ precision medicine approach has potential to increase clinical trial success rates
Poolbeg progress oral vaccine programme
Poolbeg’s platform will possess the capability to generate vaccines for a wide range of diseases
Alchemab Therapeutics reveals Alzheimer’s candidate
ATLX-1088 is regarded as a possible first-in-class human antibody targeting CD33 – a cell surface protein
Delix Therapeutics completes dose study for DLX-001
During research there were not any clinically-relevant adverse events or psychotomimetic effects
Avacta announces AVA6000 dose escalation results
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
FluoGuide announces head and neck cancer therapy results
The treatment is administered intravenously prior to surgery, lighting up cancer during surgery
BioSenic to deliver news on copper-arsenic trioxide combination
Immunological disorder therapy data to be shared at International Conference on Redox Medicine
Greener NHS and NHS Innovation Accelerator collaborate
Partnership will help NHS to prepare for fundamental change, including reducing carbon emissions
Anoat Therapeutics receives cystic fibrosis funding boost
Vital financing will be used to develop novel therapies for condition with high unmet medical need
